Navigation Links
Xenon Announces Appointment of EVP, Research & Development
Date:5/17/2010

VANCOUVER, May 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce today that it has appointed Tarek S. Mansour as Executive Vice President, Research and Development.

"We are delighted to welcome Tarek to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "Tarek is a world-class R&D executive whose experience in discovering products, a number of which are now on the market, will further enhance Xenon's capabilities.  Tarek has had the unique experience of holding senior leadership positions within both biotech and more traditional pharmaceutical companies.  His successful careers at Biochem Pharma and Wyeth Pharmaceuticals (now Pfizer) have armed Tarek with best-in-class drug discovery and development practice and we are confident that Tarek will make a major contribution to Xenon's future innovative R&D efforts."

Dr. Mansour has spent nearly 25 years in the life sciences industry with positions at Biochem Pharma, and Wyeth Pharmaceuticals (now Pfizer). His most recent position at Wyeth Research was as VP, Chemical Sciences Head over multiple research sites. Dr. Mansour received his PhD in Chemistry from the University of Missouri - Columbia.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biologic Products Announces First Quarter 2010 Results
2. Dehaier Medical Systems Announces First Quarter Net Income Up 54%
3. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
4. Still River Systems Announces Production Milestone for the Worlds Smallest High-Energy Proton Therapy Accelerator
5. joimax(R) Holds the First International TESSYS(R) User Meeting in Veenhuizen, The Netherlands, and Announces the Launch of Various New Products for Endoscopic Spinal Surgery
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
8. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
9. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
10. Cogdell Spencer Announces Commencement of Common Stock Offering
11. Mylan Announces Upsizing and Pricing of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 BioNovus Innovations LLC and the ... Medical Innovation (IAMI) today announced a new partnership ... medical devices. An agreement between the ... license, develop and commercialize medical innovations advanced through ... partnership represents a significant advance in our ability ...
(Date:5/3/2016)... May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, ... - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... BROOMALL, Pa. , May 3, 2016 ... Attorney Jack Whelan and Delaware County ... NARCAN® (naloxone HCI) Nasal Spray in all ACME ... the U.S. Centers for Disease Control and Prevention (CDC), naloxone has ... 2014, when police officers in Delaware County ...
Breaking Medicine Technology:
(Date:5/6/2016)... TX (PRWEB) , ... May 06, 2016 , ... ... of Bluvault's Integration Service, their latest implementation service offering for global clients of ... ( Appterra ). , Bluvault’s Integration Service is a key component in ...
(Date:5/6/2016)... IL (PRWEB) , ... May 06, 2016 , ... From ... in Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s ... for independent practice growth. , “It is our priority to see practices succeed in ...
(Date:5/6/2016)... San Diego, CA (PRWEB) , ... May 06, 2016 , ... ... of Companies, has been family-owned and operated for over 35 years. Maintaining core values ... community has driven their success and made them a leading name in San Diego ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, ... Cardiovascular Institute of the South announced today that Dr. Robert Menuet, Interventional Cardiologist ... an Intravascular Ultrasound Guided Coronary Atherectomy. , This procedure involves the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... in the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 ... assessed organizations that specialize in consulting services for electronic health record (EHR) solutions ...
Breaking Medicine News(10 mins):